Literature DB >> 21719286

Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.

Christophe Antczak1, David Shum, Bhramdeo Bassit, Mark G Frattini, Yueming Li, Elisa de Stanchina, David A Scheinberg, Hakim Djaballah.   

Abstract

Selective inhibitors of human peptide deformylase (HsPDF) are predicted to constitute a new class of antitumor agents. We report the identification of benzofuran-4,5-diones as the first known selective HsPDF inhibitors and we describe their selectivity profile in a panel of metalloproteases. We characterize their structure-activity relationships for antitumor activity in a panel of cancer cell lines, and we assess their in vivo efficacy in a mouse xenograft model. Our results demonstrate that selective HsPDF inhibitors based on the benzofuran-4,5-dione scaffold constitute a novel class of antitumor agents that are potent in vitro and in vivo.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21719286      PMCID: PMC3139024          DOI: 10.1016/j.bmcl.2011.05.129

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  16 in total

1.  Activity-based probes for the proteomic profiling of metalloproteases.

Authors:  Alan Saghatelian; Nadim Jessani; Arul Joseph; Mark Humphrey; Benjamin F Cravatt
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-25       Impact factor: 11.205

Review 2.  Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.

Authors:  Christopher M Overall; Oded Kleifeld
Journal:  Nat Rev Cancer       Date:  2006-03       Impact factor: 60.716

Review 3.  Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.

Authors:  C A Kontogiorgis; P Papaioannou; D J Hadjipavlou-Litina
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

4.  Design and synthesis of substrate analogue inhibitors of peptide deformylase.

Authors:  T Meinnel; L Patiny; S Ragusa; S Blanquet
Journal:  Biochemistry       Date:  1999-04-06       Impact factor: 3.162

5.  Structure and activity of human mitochondrial peptide deformylase, a novel cancer target.

Authors:  Sindy Escobar-Alvarez; Yehuda Goldgur; Guangli Yang; Ouathek Ouerfelli; Yueming Li; David A Scheinberg
Journal:  J Mol Biol       Date:  2009-02-21       Impact factor: 5.469

6.  Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics.

Authors:  Mona D Lee; Yuhong She; Michael J Soskis; Christopher P Borella; Jeffrey R Gardner; Paula A Hayes; Benzon M Dy; Mark L Heaney; Mark R Philips; William G Bornmann; Francis M Sirotnak; David A Scheinberg
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

7.  Characterization of the Thermus thermophilus locus encoding peptide deformylase and methionyl-tRNA(fMet) formyltransferase.

Authors:  T Meinnel; S Blanquet
Journal:  J Bacteriol       Date:  1994-12       Impact factor: 3.490

8.  Characterization of a human peptide deformylase: implications for antibacterial drug design.

Authors:  Kiet T Nguyen; Xubo Hu; Craig Colton; Ratna Chakrabarti; Michael X Zhu; Dehua Pei
Journal:  Biochemistry       Date:  2003-08-26       Impact factor: 3.162

9.  An unusual peptide deformylase features in the human mitochondrial N-terminal methionine excision pathway.

Authors:  Alexandre Serero; Carmela Giglione; Alessandro Sardini; Juan Martinez-Sanz; Thierry Meinnel
Journal:  J Biol Chem       Date:  2003-10-07       Impact factor: 5.157

10.  Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation.

Authors:  D Mazel; S Pochet; P Marlière
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

View more
  1 in total

1.  Overexpression of peptide deformylase in breast, colon, and lung cancers.

Authors:  Harsharan Randhawa; Shireen Chikara; Drew Gehring; Tuba Yildirim; Jyotsana Menon; Katie M Reindl
Journal:  BMC Cancer       Date:  2013-07-01       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.